Answers are grounded in this paper and cite their sources.
Compares efficiency and safety of tenecteplase to alteplase in acute ischemic stroke, indicating improved workflow.
Background and aims Tenecteplase (TNK) offers pharmacological advantages over alteplase (rt-PA) and is increasingly used for intravenous thrombolysis (IVT) in acute ischemic stroke (AIS). Our stroke center switched from rt-PA to TNK in June 2024, enabling a real-world comparison of treatment efficiency and safety across conventional, extended treatment, and other off-label scenarios. Methods We retrospectively analyzed our stroke registry including all AIS patients treated with IVT 12 months before (rt-PA: June 2023–May 2024) and after (TNK: June 2024–May 2025) the transition. IVT was administered within ≤4.5 hours, >4.5 hours and in selected off-label settings, including under oral anticoagulation. Primary endpoints were in-hospital workflow times (door-to-needle [DTN], door-to-imaging [DTI], imaging-to-needle [ITN], door-to-groin, door-to-recanalization). Safety endpoints included any intracranial hemorrhage (ICH) and symptomatic ICH (sICH; SITS-MOST). Propensity score matching (PSM) and adjusted analyses were applied. Results Overall, 591 patients received IVT (rt-PA n=278; TNK n=313); 69% were treated within ≤4.5 hours and 31% beyond. TNK was associated with shorter DTN times compared with rt-PA (31 [IQR 22–48] vs. 35 min [26–54]; p=0.002), driven by reduced ITN times (12 [7–25] vs. 16 min [9–29]; p<0.001). Safety outcomes were comparable, confirmed by PSM and adjusted analyses with no significant differences in any ICH (8% vs. 7%; p=0.61) or sICH (3% vs. 1%; p=0.34) and no increase in hemorrhagic complications in aforementioned off-label scenarios. Conclusions Transitioning from rt-PA to TNK significantly improved in-hospital workflow efficiency while maintaining comparable safety in routine clinical practice, supporting TNK as a first-line thrombolytic agent. Conflict of interest Alexander Sekita: nothing to disclose; Kosmas Macha: nothing to disclose; Ludwig Singer: nothing to disclose; Stefan Schwab: nothing to disclose; Stefan T. Gerner: nothing to disclose;
No takes yet. Share an insight, caveat, or question.
Sekita et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: